Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study

Liang,Yong‑Rong; Guo,Zhe; Jiang,Jing‑Hang; Xiang,Bang‑De; Li,Le‑Qun

doi:10.3892/ol.2016.5121

Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study

Authors:
- Yong‑Rong Liang
- Zhe Guo
- Jing‑Hang Jiang
- Bang‑De Xiang
- Le‑Qun Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Wuhan, Hubei 430000, P.R. China, Department of General Surgery, The Second People's Hospital of Jingmen, Jingmen, Hubei 448000, P.R. China
Published online on: September 12, 2016 https://doi.org/10.3892/ol.2016.5121
Pages: 3513-3518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical efficacy of thymosin α1 (Tα1) therapy in patients with hepatocellular carcinoma (HCC) subsequent to radical hepatectomy is unclear. In the present study, the impact of Tα1 therapy on outcomes in HCC patients after radical hepatectomy was retrospectively evaluated. Medical records were retrospectively reviewed for 146 patients with hepatitis B virus (HBV)-associated HCC who were treated by radical hepatectomy and subsequently with Tα1 therapy, as well as for 412 control patients with HBV‑associated HCC treated by radical hepatectomy. Propensity score matching was used to minimize confounding variables due to baseline differences. Liver function, recurrence‑free survival and overall survival rates were compared between the two groups. Serum markers of liver function were significantly improved in the Tα1 group compared with the control group. The 1‑, 2‑ and 3‑year overall survival rates were 87.2, 82.0 and 68.4% in the Tα1 group and 78.2, 64.2 and 49.7% in the control group (P=0.011). The 1‑, 2‑ and 3‑year recurrence‑free survival rates were 79.7, 70.8 and 67.3% in the Tα1 group and 69.9, 61.5 and 51.6% in the control group (P=0.019). The results suggested that post‑hepatectomy Tα1 therapy improves liver function and significantly prolong recurrence‑free and overall survival in patients with HBV‑associated HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD and Li LQ: Comparison of survival of patients with BCLC stage a hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: A propensity score-based analysis. Ann Surg Oncol. 21:3069–3076. 2014. View Article : Google Scholar : PubMed/NCBI
3	Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L and Tang ZY: Risk factors, prognosis and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 18:1955–1963. 2011. View Article : Google Scholar : PubMed/NCBI
4	Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA and Pawlik TM: Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: A Multi-Institutional analysis. Ann Surg Onco. 21:147–154. 2014. View Article : Google Scholar
5	Forner A, Llovet J and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhong JH, Ma L, Wu LC, Zhao W, Yuan WP, Wu FX, Zhang ZM, Huang S, You XM and Li LQ: Adoptive immunotherapy for postoperative hepatocellular carcinoma: A systematic review. Int J Clin Pract. 66:21–27. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lee SC: Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol. 20:3112–3124. 2014. View Article : Google Scholar : PubMed/NCBI
8	You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, et al: Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J Gastroenterol. 12:6715–6721. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ and Lee HS: Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 47:1048–1055. 2012. View Article : Google Scholar : PubMed/NCBI
10	Matteucci C, Minutolo A, Sinibaldi-Vallebona P, Palamara AT, Rasi G, Mastino A and Garaci E: Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann N Y Acad Sci. 1194:6–19. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Zhao YX and Mo ZW: Influence of thymosin α1 on postoperative recurrence of primary liver cancer. Chin J Hepatobil Surg. 10:592–593. 2004.(In Chinese).
12	Palmieri G, Biondi E, Morabito A, Rea A and Bianco A: Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis? Oncol Rep. 3:655–656. 1996.PubMed/NCBI
13	Zhong J, Ke Y, Gong W, Xiang BD, Ma L, Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X and Li LQ: Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 8:e681932013. View Article : Google Scholar : PubMed/NCBI
15	Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY, Bae HI, Yun YK and Hwang YJ: Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 103:148–151. 2011. View Article : Google Scholar : PubMed/NCBI
17	Poon RT: Differentiating early and late recurrences after resection of HCC in cirrhotic patients: Implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 16:792–794. 2009. View Article : Google Scholar : PubMed/NCBI
18	Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P and Sinibaldi-Vallebona P: Thymosin α1 and cancer: Action on immune effector and tumor target cells. Ann N Y Acad Sci. 1269:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
19	Nitta H, Beppu T, Imai K, Hayashi H, Chikamoto A and Baba H: Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg. 37:1034–1042. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD and Wu GB: Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. Eur J Surg Oncol. 38:286–295. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wu C, Chen Y, Ho HJ, Hsu YC, Kuo KN, Wu MS and Lin JT: Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 308:1906–1913. 2012. View Article : Google Scholar : PubMed/NCBI